Results 241 to 250 of about 41,944 (264)

Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.

JAMA Oncology
Importance Olaparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that provides benefit in combination with hormonal therapies in patients with metastatic prostate cancer who harbor homologous recombination repair (HRR) alterations.
C. Marshall, Benjamin A. Teply, Jiayun Lu, L. Oliveira, Hao Wang, S. Mao, W. Kelly, C. Paller, M. Markowski, S. Denmeade, Serina King, R. Sullivan, E. Davicioni, J. Proudfoot, M. Eisenberger, M. Carducci, T. Lotan, E. Antonarakis   +17 more
semanticscholar   +1 more source

Cediranib and Olaparib Combination Compared To Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005

Journal of Clinical Oncology
PURPOSE We assessed the efficacy of cediranib, olaparib, and cediranib/olaparib compared with standard-of-care chemotherapy (SOC) in platinum-resistant or platinum-refractory epithelial ovarian cancer (PROC).
Jung-min Lee, M. Brady, Austin Miller, R. Moore, Helen Mackay, Leah McNally, J. Lea, Daron G. Street, Stephanie Lheureux, Megan E McDonald, Linda R. Duska, Guilherme Cantuaria, J. Kavecansky, C. Leath, Matthew Powell, M. Cadungog, Peter G. Rose, Yong-Man Kim, Helen Q. Huang, Michèle Provencher, L. Wenzel, Michael Bookman, Elise C Kohn, A. Secord   +23 more
semanticscholar   +1 more source

BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).

Journal of Clinical Oncology
19 Background: Deleterious germline or somatic HRRm are present in about 20% of mCRPC patients (pts). Preclinically, PARP-inhibition demonstrated synergism with AR-targeted therapy.
M. Hussain, Masha Kocherginsky, N. Agarwal, N. Adra, Jingsong Zhang, C. Paller, J. Picus, Z. Reichert, R. Szmulewitz, S. Tagawa, Timothy Kuzel, Latifa A Bazzi, S. Daignault-Newton, Y. Whang, R. Dreicer, Ryan D Stephenson, Matthew B. Rettig, D. Shevrin, A. Chinnaiyan, E. Antonarakis   +19 more
semanticscholar   +1 more source

Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial.

European Urology Oncology
BACKGROUND AND OBJECTIVE In PROpel (NCT03732820), olaparib + abiraterone resulted in a statistically significant radiographic progression-free survival (rPFS) benefit and numerically prolonged overall survival (OS) versus placebo + abiraterone in first ...
N. Clarke, A. Armstrong, M. Oya, N. Shore, G. Procopio, João Daniel Guedes, Cagatay Arslan, N. Mehra, Francis X. Parnis, E. Brown, F. Schlürmann, Jae Young Joung, M. Sugimoto, Oliver Sartor, C. Poehlein, David McGuinness, A. Degboe, Fred Saad   +17 more
semanticscholar   +1 more source

Olaparib

Drugs of the Future, 2009
null Vasiliou, S., null Castaner, R., null Bolos, J.   +2 more
openaire   +1 more source

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

Annals of Oncology, 2021
Jürgen Geisler, Violeta Serra, Hans Petter Eikesdal   +2 more
exaly  

Two‐step flow synthesis of Olaparib in microreactor: Route design, process development and kinetics research

Chemical Engineering Journal, 2023
Qilin Xu, Yongjun Zang, Guosi Li
exaly  

Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer

Gynecologic Oncology, 2022
Nicoletta Colombo, Federica Tomao
exaly  

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Annals of Oncology, 2021
exaly  

Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice

European Journal of Pharmaceutical Sciences, 2022
Yoo-Kyung Song, Min-Soo Kim, Suk-Jae Chung   +2 more
exaly